BSX invests $1.5B in MiRus for TAVR option, adding structural heart bet

What happened

Boston Scientific invested $1.5B for a 34% stake in MiRus, gaining an exclusive option to acquire a balloon-expandable TAVR system using a proprietary rhenium alloy. The move expands BSX's structural heart portfolio beyond Watchman but adds to an already full plate of Penumbra integration and core procedure growth deceleration. The TAVR market is dominated by Edwards and Medtronic, and MiRus's technology is early-stage without approved products. While the option provides a long-term growth avenue, the upfront cash outlay increases leverage and management distraction at a time when net debt/EBITDA already stands at 2.8x. The market should view this as a high-risk bet that does not materially alter the near-term thesis, which hinges on Watchman expansion and Penumbra execution.

Implication

Monitor MiRus clinical progress and TAVR market share potential; deal increases leverage and could lead to impairments if growth assumptions prove optimistic, but if successful diversifies structural heart exposure and could support long-term re-rating.

Thesis delta

The investment adds a new structural heart catalyst (TAVR optionality) but increases leverage and execution risk, shifting the thesis from a focused Watchman/EP growth story to a multi-platform strategy that could either amplify returns or stretch resources.